Select country set
Menu Shopping cart 0,00 Search
Distributed product

Rat-MID™ Osteocalcin ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antigen
  • Other names:OST, bone Gla protein, B.G.P
  • Species:Rat
Please select your region to see available products and prices.
Cat. No. Size Price

AC-12F1 96 wells
PubMed Product Details
Technical Data


Competitive ELISA, Immobilized antigen


The Rat-MID™ Osteocalcin EIA is an enzyme-linked immunosorbent assay for the quantitative determination of osteocalcin in rat serum and plasma. The assay is for research use only. The clinical utility of rat osteocalcin as a marker for bone turnover has been evaluated in several preclinical settings. It has been reported that the serum level increases after ovariectomy and this oestrogen deficiency-induced state can be prevented by treatment with either oestrogen, selective oestrogen receptor modulators (SERMs) or bisphosphonates.

Scientific Description:

Osteocalcin or bone Gla protein (BGP) is a major non-collagenous protein of the bone matrix. It has a molecular weight of approximately 6000 Dalton and consists in most species of 49 amino acids; however, rat osteocalcin consists of 50 amino acids. Osteocalcin has a unique property for binding to calcium facilitated by the presence of 2-3 gamma-carboxyglutamic acids at position 17, 21 and 24. The mid-molecular part of osteocalcin, especially the amino acids between 20 and 30, exhibits a high degree of inter-species conservation. The Rat-MID™ Osteocalcin EIA is based upon the competitive binding of a monoclonal antibody to soluble osteocalcin or to immobilised osteocalcin. Briefly, the monoclonal antibody is raised against human osteocalcin and recognizes the mid-molecular part (amino acids 21-29) of the molecule.


Serum, Plasma

Sample Requirements

20 μL/well


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0-1600 ng/mL

Limit of Detection

50.0 ng/mL



  • Easy to perform
  • Sample volume only 20 μL
  • Measures bone formation in rat serum and plasma
  • Low sample volume 20 μL
  • Multi-disciplinary use – measuring plasma and serum samples

Research topic

Bone and cartilage metabolism, Animal studies


Osteocalcin or bone Gla protein (B.G.P) is the major non-collagen protein of the bone matrix. It has a molecular weight of 5800 Da and contains 49 amino-acids, including 3 residues of gamma carboxyl glutamic acid. Osteocalcin is synthesized in the bone by the osteoblasts. After production, it is partly incorporated in the bone matrix and the rest is found in the blood circulation. The exact physiological function of osteocalcin is still unclear. A large number of studies show that the circulating levels of osteocalcin reflect the rate of bone formation. The determination of the blood levels of osteocalcin is valuable for : - The identification of women at risk of developing osteoporosis - Monitoring bone metabolism during the perimenopause and postmenopause - Monitoring bone metabolism during hormone replacement therapy and treatment of premenopausal women with LH-RH agonists - Monitoring bone metabolism in patients with growth hormone deficiency, hypothyroidism, hyperthyroidism, chronic renal failure.

Summary References (8)

References to Osteocalcin

  • Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984 May 19;1 (8386):1091-3
  • Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW, Rubens RD. Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol. 1988 Jul;24 (7):1211-7
  • Coulton LA, Preston CJ, Couch M, Kanis JA. An evaluation of serum osteocalcin in Paget's disease of bone and its response to diphosphonate treatment. Arthritis Rheum. 1988 Sep;31 (9):1142-7
  • Demiaux B, Arlot ME, Chapuy MC, Meunier PJ, Delmas PD. Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab. 1992 May;74 (5):1146-51
  • Johansen JS, Jensen SB, Riis BJ, Rasmussen L, Zachmann M, Christiansen C. Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy. J Clin Endocrinol Metab. 1990 Jul;71 (1):122-6
  • Minisola S, Scarnecchia L, Scarda A, Bigi F, Tabolli S, Valtorta C, Mazzuoli G. Serum osteocalcin in primary hyperparathyroidism: short-term effect of surgery. Miner Electrolyte Metab. 1988;14 (4):201-7
  • Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci. 1991;28 (4):287-335
  • Price PA. Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm. 1985;42:65-108
Related Products Docs